Loading
A phase 2 trial of sacituzumab tirumotecan and toripalimab in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC is a phase 2, interventional study registered as NCT07244874 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 41 participants, started 2025-12-01 and due to reach its primary completion in 2028-01-30. Interventions recorded: Sacituzumab tirumotecan; Toripalimab. Conditions listed: TNBC - Triple-Negative Breast Cancer; PD-L1 Positive. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab tirumotecan, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Toripalimab, Early triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/